Key result
Serum PTX-3 and syndecan-4 levels differ between children with chronic heart failure and healthy controls.
Why the study?
The changes and clinical significance of serum pentraxin-3 and syndecan-4 in children with chronic heart failure were not well understood.
Are serum levels of pentraxin-3 and syndecan-4 altered in children with chronic heart failure compared to healthy controls?
Case-Control (n=70)
No
Are serum levels of pentraxin-3 and syndecan-4 altered in children with chronic heart failure compared to healthy controls?
p-value: p=< 0.05
Serum PTX-3 and syndecan-4 may serve as potential biomarkers for the diagnosis and evaluation of ventricular remodeling in children with chronic heart failure.
PTX-3 and syndecan-4 merit exploration as pediatric CHF biomarkers; hypothesis-generating and should not yet change practice.
OBJECTIVE: To study the change and significance of serum pentraxin-3 (PTX-3) and syndecan-4 in children with chronic heart failure (CHF). METHODS: A total of 40 children with CHF who were admitted to the Department of Pediatrics of the First Affiliated Hospital of Zhengzhou University were enrolled as the heart failure group, and 30 children who underwent physical examination in the outpatient service during the same period of time were enrolled as the control group. The serum levels of PTX-3, syndecan-4, and N-terminal pro-brain natriuretic peptide (NT-proBNP) were compared between the two groups. RESULTS: < 0.05). CONCLUSIONS: Serum PTX-3 and syndecan-4 may be involved in the development and progression of ventricular remodeling in children with CHF and may be used as markers for the diagnosis, cardiac function grading, and treatment outcome evaluation of children with heart failure.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2021) conducted a case-control in chronic heart failure (n=70). Chronic heart failure vs. Healthy children (control group) was evaluated on Serum levels of PTX-3, syndecan-4, and NT-proBNP (p=< 0.05). Serum PTX-3 and syndecan-4 levels differed significantly between children with chronic heart failure and healthy controls (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: